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MYELOID NEOPLASIA
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Wilms tumor 1 (WT1) mutations have re-
cently been identified in approximately
10% of adult acute myeloid leukemia
(AML) with normal cytogenetics (CN-AML)
and are associated with poor outcome.
Using array-based comparative genome
hybridization in pediatric CN-AML samples,
we detected a WT1 deletion in one sample.
The other WT1 allele was mutated. This
prompted us to further investigate the
role of WT1 aberrations in childhood AML.
Mutations were found in 35 of 298 (12%)
diagnostic pediatric AML samples. In 19 of
35 (54%) samples, more than one WT1
aberration was found: 15 samples had
2 different mutations, 2 had a homozy-
gous mutation, and 2 had a mutation plus
a WT1 deletion. WT1 mutations clustered
significantly in the CN-AML subgroup
(22%; P < .001) and were associated with
FLT3/ITD (43 vs 17%; P < .001). WT1 muta-
tions conferred an independent poor prog-
nostic significance (WT1 mutated vs wild-
type patients: 5-year probability of overall
survival [pOS] 35% vs 66%, P  .002;
probability of event-free survival 22% vs
46%, P < .001; and cumulative incidence
of relapse or regression 70% vs 44%,
P < .001). Patients with both a WT1 muta-
tion and a FLT3/ITD had a dismal progno-
sis (5-year pOS 21%). WT1 mutations
occur at a significant rate in childhood
AML and are a novel independent poor
prognostic marker. (Blood. 2009;113:
5951-5960)
Introduction
Childhood acute myeloid leukemia (AML) is a heterogeneous
disease characterized by different recurrent cytogenetic aberrations
that, together with early treatment response, determine the current
risk-group classification in childhood AML.1,2 Over the past
decades, the prognosis of childhood AML patients has improved
significantly, now reaching long-term survival rates of approxi-
mately 60%.3 Further intensification of chemotherapy is not
expected to improve survival any further, as the current regimens
are already very intensive, resulting in relatively high frequencies
of treatment-related death, as well as long-term side effects.1
Instead, new therapeutic strategies are needed. Drugs that target
specific aberrations in the leukemic cells are of advantage, not only
for improving prognosis, but also as they may cause less side
effects. Therefore, the identification of new genetic aberrations that
play a role in the pathogenesis of pediatric AML is warranted. Such
aberrations may also improve classification and risk-group stratification.
In childhoodAML, approximately 20% to 25% of cases at diagnosis
cannot be characterized by karyotypic aberrations and are referred to as
cytogenetically normal AML (CN-AML). In adults, this subgroup is
larger (approximately 40%-50%), and several molecular aberrations
have been identified in this subgroup, such as mutations in NPM1,
CEBP, partial tandem duplications of the MLL gene (MLL-PTD), as
well as internal tandem duplications of the FLT3 gene (FLT3/ITD).
These molecular aberrations are also found in childhood AML, but in
a smaller percentage of childhood CN-AML compared with adult
CN-AML. In part, this is due to a 2-fold lower frequency of NPM1
mutations in children (20%-25%)4-6 compared with adults (50%-60%).7
Thus, in a relatively large cohort of childhood CN-AML, the underlying
genetic aberrations are still unknown.
To identify novel abnormalities in childhood CN-AML, we
performed array-based comparative genome hybridization (array-
CGH), and found an 11p13 deletion that included the Wilms tumor
1 (WT1) gene in 1 of 43 patients (Figure 1A). The remaining WT1
allele carried a truncating mutation (Figure 1B). This observation
focused our interest on WT1 aberrations in childhood AML, as only
limited data on this topic are available.8,9
The WT1 gene is known to be overexpressed in leukemias and,
therefore, is used as a marker for minimal residual disease (MRD)
detection, as well as a target for immunotherapy.10 The gene
encodes for a zinc-finger-motif–containing transcription factor
involved in the regulation of growth and differentiation. Although
the precise role of the WT1 protein in hematopoieses is currently
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unknown, it has been hypothesized to act both as an enhancer of
cellular quiescence in hematopoietic stem cells and as an inducer of
cellular differentiation in more committed precursor cells.10,11 WT1
mutations cause translation of an aberrant protein with loss of
normal function and might therefore result in stem cell prolifera-
tion and blocking of differentiation, thereby contributing to leuke-
mogenesis. Recently, WT1 mutations were found in approximately
10% of the adult CN-AML subgroup and were reported to be
associated with treatment failure and a poor prognosis.12-14
To determine further the role of WT1 aberrations in childhood
AML, we searched for these aberrations in a large, well-
characterized cohort of childhood AML patients. WT1 mutations
were found in 12% of diagnostic childhood AML samples and
appeared to confer independent prognostic significance.
Methods
Patient samples
Viably frozen bone marrow (BM) or peripheral blood (PB) samples taken at
diagnosis from 298 children with AML were provided by the Dutch
Childhood Oncology Group (DCOG; The Hague, The Netherlands), the
AML-Berlin-Frankfurt-Mu¨nster Study Group (AML-BFM-SG; Hannover,
Germany, and Prague, Czech Republic), and the Saint-Louis Hospital
(Paris, France). In addition, 39 paired diagnostic-relapse samples (BM or
PB) and 5 paired diagnostic-remission samples (BM) were provided by the
DCOG and AML-BFM-SG. Institutional review board approval for these
studies had been obtained from Erasmus MC-Sophia Children’s Hospital
according to local laws and regulations, and informed consent was obtained
accordance with the Declaration of Helsinki. Each national study group
Figure 1. WT1 aberrations in patient no. 1885 detected by array-CGH and sequencing. (A) The left part of the figure shows a chromosome 11 ideogram and corresponding
oligonucleotide array-CGH plot of the ratio of patient no. 1885 DNA and control DNA (blue tracing) versus the dye-swap experiment (red tracing) from an array-CGH experiment
(105-K oligonucleotide array-CGH platform; Agilent Technologies, Palo Alto, CA). A cryptic 11p13 deletion of approximately 2.5 Mb is found, which area includes the WT1 gene.
The right part of the figure zooms in on the deleted area and presents the genes located in this area. (B) Sequence analysis of patient no. 1885 showing a c.901C3T non-sense
mutation on the remaining WT1 allele.
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performed central review of the morphologic and cytogenetic classification,
as well as clinical follow-up. For a complete list of the individual study
participants in the DCOG and AML-BFM studies, see the Appendix
(available on the Blood website; see the Supplemental Materials link at the
top of the online article).
After thawing of the samples, contaminating nonleukemic cells were
eliminated as previously described.15 Blast percentages were assessed morpho-
logically on May-Gru¨nwald-Giemsa–stained cytospin slides. Genomic DNAand
total cellular RNA were extracted from leukemic cells using TRIzol reagent
(Invitrogen, Breda, The Netherlands) as described before.16
Samples were routinely screened using standard chromosome banding
analysis by the national study groups and were analyzed further in our
laboratory for recurrent nonrandom genetic abnormalities, including
t(15;17), inv(16), t(8;21), and MLL gene rearrangements, using reverse
transcription polymerase chain reaction (RT-PCR) and/or fluorescent in situ
hybridization.
Treatment protocols
WT1 mutation analysis was performed on samples obtained from patients
who were treated between 1987 and 2005, according to consecutive
AML-BFM-SG/DCOG and to Leuca´mie Aique¨ Mye´loïde Enfant (LAME)
collaborative childhood AML treatment protocols. The survival analysis
was, however, restricted to the patients included in the AML-BFM-SG/
DCOG cohorts, to reduce the variability in treatment regimens, and because
this comprised the majority of patients (n  232). Details of the treatment
protocols included in the survival analysis and overall outcome data have
been previously published, with the exception of study AML-BFM 04,
which is ongoing.17-19 In these protocols, treatment consisted of 4 to
5 blocks of intensive chemotherapy, using a standard cytarabine and
anthracycline backbone. Stem cell transplantation (SCT) in CR1 was used
only in selected high-risk patients.
Mutation analysis of WT1
For mutation analysis of exons 7 through 10 of the WT1 gene, genomic
DNA was PCR-amplified using specific primers described in Table S1. The
following PCR conditions were used: 2 minutes at 50°C, 10 minutes at
95°C, 40 cycles of 15 minutes at 95°C and 1 minute at 60°C, and an
extension step of 10 minutes at 72°C. Purified PCR products were directly
sequenced from both strands using the described primers. The sequence
data were analyzed using CLC Workbench version 3.5.1 (CLC Bio, Aarhus,
Denmark). WT1 mutants without an unambiguously identified sequence or
containing more than one WT1 mutation were confirmed by cloning using
the TOPO-TA Cloning kit (Invitrogen). Plasmid DNA from multiple
isolated clones was purified and directly sequenced from both strands.
To explore the presence of mutations in the other exons of the WT1
gene, exons 1-6 were screened in a cohort of 68 patients, which included
28 patients with WT1 mutations in exons 7-10 and 40 patients with
wild-type WT1 for exons 7-10. For mutation analysis of exons 1-6, the
purified DNA was subjected to 41 cycles of PCR using a touchdown
approach of 30 minutes at 94°C, 30 minutes at 66°-54°C (1  66°C,
2  64°C, 3  62°C, 4  60°C, 5  58°C, 6  56°C, and 20  54°C) and
30 minutes at 72°C using (M13-tagged) primers also described in Table S1.
PCR products were directly sequenced unidirectionally using M13-primers
and analyzed using Codoncode aligner (Codoncode, Dedham, MA).
Mutations were confirmed by an independent amplification of the fragment
and direct sequencing of both strands. This method used for analysis of
exons 1 to 6 has originally been developed for mutation detection in
nephroblastomas.
Expression analysis of mutated WT1
To confirm the expression of mutated WT1, cDNA of WT1 exon 7-mutated
samples was PCR-amplified using specific primers described in Table S1.
PCR and direct sequencing conditions were the same as for WT1 mutation
analysis on genomic DNA as described above.
For quantitative expression analysis, quantitative RT-PCR of mutated
WT1 samples was performed as described before.20,21
Multiplex ligation-dependent probe amplification
Multiplex ligation-dependent probe amplification (MLPA) was used to
detect small deletions in the WT1 gene. MLPA analysis was performed
using the SALSA MPLA Kit P118 (MRC Holland, Amsterdam, The
Netherlands). SALSA P118 consists of one reaction mixture containing
probes for all WT1 exons and 20 control probes in other regions of the
genome. The exact location of the MLPA probes can be downloaded from
the MRC Holland website (http://www.mrc-holland.com). MPLA was
carried out according to the manufacturer’s protocol. Electrophoresis of
MLPA-PCR products was done on an ABI-Prism 310 (Applied Biosystems,
Foster City, CA). Data analysis was performed by exporting the peak areas
to Microsoft Excel. Sample-related and peak-related differences in PCR
and electrophoresis efficiency were corrected by first calculating the peak
area relative to the sum of peak areas per sample and subsequently
calculating each normalized peak area relative to the mean of that peak in
control samples. Peak heights outside the range 0.7 to 1.3 times the control
peak height were considered abnormal, with those below 0.7 representing
deletions, and those above 1.3 representing duplications. Several control
samples were included in each MLPA test.
Mutation analysis of other molecular aberrations
Detection of other molecular aberrations, including mutations of CEBP,
FLT3/ITD and TKD, NPM1, N-RAS and K-RAS, PTPN11 and c-KIT, was
performed as previously described.6,22-25 The detection of MLL-PTD was
done with PCR as previously described26 and confirmed with MLPA (MRC
Holland). The reaction mixture for MPLA-analysis contained probes for
exons 2 through 13 of the MLL gene and exon 17 as internal control.
A probe in the serpinB2 gene was used as external control (manuscript
submitted; primers available on request). MLPA was performed according
to the manufacturer’s protocol. Data were analyzed using GeneMarker
version 1.5 (SoftGenetics, State College, PA).
Statistical analysis
To compare categorical variables we used 2 analysis and the Fisher exact
test for small patient numbers. The nonparametric Mann-Whitney U test
was applied for continuous variables.
To assess outcome, the following parameters were used: complete
remission (CR) rate, resistant disease (RD; defined as failure to achieve
remission but excluding patients with early death), probability of event-free
survival (pEFS; defined as time between diagnosis and first event, including
relapse, death by any cause, failure to achieve remission or second
malignancy), probability of overall survival (pOS; defined as time between
diagnosis and death from any cause), and the cumulative incidence of
relapse or nonresponse (CIR; defined as time between diagnosis and
relapse; resistant disease was included as an event on day 0). pEFS and pOS
were estimated by the Kaplan-Meier method and compared using the
log-rank test. The CIR curves were constructed by the method of
Kalbfleisch and Prentice and were compared using Gray test. The indepen-
dence of prognostic factors was examined by multivariate Cox regression
analysis.
P values less than .05 were considered statistically significant (2-tailed
testing).
Results
Study population
We screened 298 diagnostic childhood AML samples for WT1
mutations. The patient characteristics are shown in Table 1.
Survival analysis was restricted to the patients who were treated
using uniform protocols (n  232); hence patients treated accord-
ing to other protocols were excluded (n  39). In addition, patients
with promyelocytic leukemia-retinoic acid receptor  (PML-
RAR; n  15), secondary AML (n  8), treatment without cura-
tive intent (n  1), and patients lost to follow-up (n  3) were
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excluded. The WT1-mutated and WT1 wild-type AML patients
were equally distributed over the different treatment protocols
(P  .43), and there was no significant difference between the
treatment protocols in terms of pEFS and pOS (respectively,
P  .75 and P  .38). The patient characteristics of the cohort used
for survival analysis are shown in Table S2.
WT1 mutation analysis
We first analyzed the samples for mutations in the hotspot areas
exons 7-10 of the WT1 gene. A total of 48 WT1 gene mutations
were detected in 34 of the 298 (11.4%) samples. These mutations
predominantly clustered in 2 areas in exon 7 (n  41), but were
also found in exon 8 (n  1) and exon 9 (n  4; Table 2). In
2 cases, WT1 mutations were detected in intron 6-7, located on the
splice-acceptor site; these mutations are predicted to disrupt the
splice site of exon 7 and are therefore considered pathogenic.
Subsequently, a subset of 68 patients was also analyzed for
mutations in exons 1 to 6, and additional mutations were found in
exon 1 (n  2), exon 2 (n  1), and exon 3 (n  2). The mutations
in exons 1, 2, and 3 occurred only in the samples harboring an exon
7 mutation as well, except for one sample that carried both an exon
2 and 3 mutation. Therefore, the total number of mutations detected
in the WT1 gene was 53 mutations in 35 of 298 (11.7%) samples.
The locations and hotspots of the WT1 mutations are presented
schematically in Figure 2.
Most of the WT1 mutations were frame-shift mutations
(n  41) predominantly caused by insertions (range, 1-76 bp)
but also by deletions (range, 1-32 bp). Six mutations were
non-sense mutations. The frame-shift and non-sense mutations
are predicted to result in truncated proteins and, when occurring
in exon 7, to the loss of the zinc-finger DNA-binding motif of
the WT1 protein. The remaining mutations (n  6) were mis-
sense mutations leading to substitutions of single amino acids.
One of these occurred in exon 9 (c.1186GA), which is a
known pathogenic mutation in the Denys-Drash syndrome.27
The other 5 missense mutations occurred in exon 7, besides a
frame-shift mutation in exon 7.
Apart from the 53 pathogenic mutations, we also detected
mutations that we considered to be nonpathogenic. In 3 cases, silent
mutations, which do not result in amino acid changes, were found.
In 6 patients, an identical single base-pair substitution was detected
in intron 6-7, which is located 9 nucleotide positions before the
start of exon 7 (c.895-9TC). However, both the lack of a
transcript variant in these patients (data not shown) and the analysis
of this substitution with regard to the splice-donor and splice-
acceptor sites indicated no influence on splicing. These mutations
were therefore regarded as nonpathogenic. In one patient, a
missense mutation in exon 1 (c.124CT), causing the substitution
of the amino acid proline by a serine, was found. No germ line
sample or material of the parents was available to test the
leukemic-specific origin of this mutation. However, neither this
mutation nor the affected codon has been described before in
malignancies. Therefore, we regarded this mutation as an unclassi-
fied variant. Several known single-nucleotide polymorphisms
(SNPs) were found. One known SNP (c.903AG) is situated in the
mutational hotspot of exon 7 and was detected in 72 of the
298 diagnostic samples (24%). The frequency of this SNP was not
different between AML samples harboring a WT1 mutation com-
pared with WT1 wild-type samples (respectively, 8/35 [23%] vs
64/263 [24%]).
WT1 microdeletions
To evaluate microdeletions of the WT1 gene, which might act as a
mechanism of knockdown of the other WT1 allele, we used the MLPA
Table 1. Clinical and genetic characteristics of the 298 childhood AML patients included in this study, divided by WT1 mutational status
All patients WT1 mutated WT1 wild-type P
Number (%) 298 (100%) 35 (11.7%) 263 (88.3%)
Median age, y 9.7 9.2 9.7 .34
 3 y, n (%) 60 1 (2%) 59 (98%)
 3 and  10 y, n (%) 93 17 (18%) 76 (82%) .008
 10 y, n (%) 145 17 (12%) 128 (88%)
Sex (% female) 46.6% 48.6% 46.4% .81
WBC,  109/L, median (range) 38.0 (0.0-534.6) 57.2 (2.5-332.0) 34.1 (0.0-534.6) .007
FAB, n (%) .60
M0 15 (5%) 4 (12%) 11 (4%)
M1 37 (13%) 6 (18%) 31 (12%)
M2 66 (23%) 7 (21%) 59 (23%)
M3 21 (8%) 2 (6%) 19 (8%)
M4 72 (25%) 8 (24%) 64 (25%)
M5 61 (21%) 7 (21%) 54 (21%)
M6 6 (2%) 0 (0%) 6 (2%)
M7 9 (3%) 0 (0%) 9 (4%)
Other 2 (1%) 0 (0%) 2 (1%)
Unknown 9 (3%) 1 (3%) 8 (3%)
FLT3/ITD (n  298), n (%) 60 (20%) 15 (43%) 45 (17%)  .001
Median allelic ratio (range) 0.59 (0.21-2.33) 0.69 (0.32-1.25) 0.58 (0.21-2.33) .22
Median ITD length (range) 54 (18-209) 51 (18-90) 55 (20-209) .44
N- or K-RAS (n  282), n (%) 63 (22%) 8 (25%) 55 (22%) .70
c-KIT (n  283), n (%) 18 (6%) 0 (0%) 18 (7%) .24
CEBP (n  250), n (%) 20 (8%) 5 (19%) 15 (7%) .03
MLL-PTD (n  251), n (%) 6 (2%) 0 (0%) 6 (3%)  .999
NPM1 (n  293), n (%) 24 (8%) 0 (0%) 24 (9%) .09
WBC indicates white blood cell count at diagnosis; and FAB, French-American-British morphology classification.
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technique to screen 24 samples (19 WT1-mutated and 5 WT1 wild-type
samples) for deletions of exons 1 to 10. The WT1 deletion already
detected by array-CGH (patient 2 in Table 2) was again confirmed by
MLPA. One other patient, who appeared to carry a homozygous
mutation in exon 8 as detected by sequencing (patient 28 in Table 2),
actually harbored a deletion of one WT1 allele. No other sample carried
WT1 microdeletions. One patient (patient 9 in Table 2) showed a
duplication of exon 7 by MLPA. However, this observation could be
explained by an exon 7 mutation in this patient, which consisted of a
duplication of 76 bp, in which the MLPA probe was exactly situated.
Table 2. Characteristics of the WT1 aberrations detected in the diagnostic samples of 35 childhood AML patients
UPN Mutation(s)* Exon Type of mutation
Protein
level†
More than one
allele affected?
1 c.905delGinsCC 7 frame-shift yes
c.902_938dup37 7 frame-shift
c.943TC 7 missense p.Ser316Pro
2 c.901CT 7 nonsense p.Arg301X yes
del11p13, including WT1‡
3 c.934_935insA 7 frame-shift yes
c.979TC 7 missense p.Tyr327His
4 c.920_932del13;934CG 7 frame-shift no
5 c.524CA 2 nonsense p.Ser175X unknown
c.584_585insCCGG 3 frame-shift
6 c.938CA 7 nonsense p.Ser313X yes
c.935_939dupCGGTC 7 frame-shift
7 c.938_939dupTC 7 frame-shift no
8 c.905delGinsCC 7 frame-shift no
9 c.934_1009dup76 7 frame-shift no
10 c.901CT;904_905insGA 	 901CT;904_905insGA 7 nonsense plus frame-shift p.Arg301X yes
11 c.933delA 7 frame-shift yes
c.1188_1189ins17 9 frame-shift
12 c.1186GA 9 missense p.Asp396Asn no
13 c.937_940dupTCGG 7 frame-shift no
14 c.901delCinsGCG 7 frame-shift no
15 c.937_940dupTCGG 7 frame-shift no
16 c.905delGinsCC 7 frame-shift yes
c.926_935del10ins12 7 frame-shift
17 c.905_906insTT 7 frame-shift yes
c.895-1_901GGATGTGCCAACGGG 7 frame-shift plus affects splice site
18 c.937_938insG 	 937_938insG 7 frame-shift yes
19 c.905_906ins17 7 frame-shift yes
c.924_925insGG 7 frame-shift
20 c.934_935insG 7 frame-shift no
21 c.924_925insGGTT 7 frame-shift yes
c.938_939insG 7 frame-shift
22 c.933delA;937_939delTCG;1012TC 7 frame-shift yes
c.937_940dupTCGG 7 frame-shift
23 c.593delC 3 frame-shift unknown
c.901delCinsGG 7 frame-shift
24 c.398insT 1 frame-shift unknown
c.907_908insAT 7 frame-shift
25 c.901_902insG;935GA 7 frame-shift no
26 c.1173_1174insA 9 frame-shift no
27 c.442_442	2GGTTTG 1 affects splice site unknown
c.901_902insG 7 frame-shift
28 c.1072_1073insC 8 frame-shift yes
del 11p13, including WT1§
29 c.937_940dupTCGG 7 frame-shift no
30 c.934delCinsGG 7 frame-shift no
31 c.933_937dupACGGT 7 frame-shift no
32 c.1168CT 9 nonsense p.Arg390X no
33 c.895-55_895-2del54insCA intron 6-7 affects splice site yes
c.938CA 7 nonsense p.Ser313X
c.1006AG 7 missense p.K336G
34 c.898_929del32 7 frame-shift no
35 c.900_901insG 7 frame-shift no
UPN indicates unique patient number; nd, not done.
*Mutations are described according to the coding DNA sequence (RefSeq NM_0.46642).
†All frame-shift mutations are predicted to produce truncated proteins.
‡Detected by array-CGH and comfirmed by MLPA.
§Detected by MLPA.
Mutation is known to be pathogenic in Denys-Drash syndrome.
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Frequent biallelic involvement of WT1 aberrations
In 19 of 35 (54%) of the WT1-mutated samples, we detected more than
one WT1 aberration. This included either a different WT1 mutation
(n 15), a homozygous WT1 mutation (n 2), or a deletion of the
other WT1 allele (n 2; Table 2). The WT1 deletions were detected by
array-CGH and MLPA as described above. Of the 2 patients with
homozygous mutations, one was screened with MLPA and did not
harbor a deletion, but showed homozygosity of all the SNPs in the
11p13 area. This suggests that in this patient a loss of heterozygosity has
occurred due to uniparental disomy (UPD) of 11p13. Of the 15 samples
with more than one different WT1 mutation, 12 samples in fact harbored
2 mutations, and 3 samples each had 3 different mutations. In 11 of the
15 cases, we were able to perform cloning of the PCR products followed
by direct sequencing to investigate monoallelic or biallelic involvement
of the different mutations. This showed more than one affected allele in
10 of 11 cases. The patient (patient 25 in Table 2), who did not show
biallelic involvement of the 2 different mutations, had, in addition to a
common frame-shift mutation, a missense mutation in exon 7 on the
same allele.
In conclusion, we could show that at least 14 of 35 (40%) of the
WT1-mutated samples had more than one WT1 allele affected, that
is, 11 cases where both alleles were mutated but with different
mutations; 2 cases with a homozygous mutation; and 2 cases with a
mutation and a deletion of the other WT1-allele.
Expression of the mutated WT1 gene
WT1 transcripts of 16 WT1-mutated samples showed the pres-
ence of the identical mutations as identified on genomic DNA,
indicating that the mutated WT1 gene is expressed at transcrip-
tional level.
Quantitative analysis of WT1 expression was performed in
9 WT1-mutated and 9 WT1 wild-type samples. The median
expression (normalized to ABL copies  10 000) was 4.1  103
(range, 9.1  102-3.6  104) in the WT1-mutated samples,
which was comparable with the expression measured in the
wild-type samples (2.9  103; range, 4.8  102-7.7  103). Three
of the 9 WT1-mutated samples harbored mutations located
exactly at the binding site of the reversed primer used for the
quantitative RT-PCR; however, the expression of these samples
was still detectable, suggesting that the PCR amplification was
relatively unaffected by the mutations in these samples.
Paired diagnostic-remission and diagnostic-relapse samples
The WT1 mutations were not detectable in the remission material of
5 patients with WT1-mutated AML, hence suggesting somatic
origin of the WT1 mutations.
To investigate the clonal stability of WT1 mutations, we
screened 39 diagnostic-relapse pairs. This included 11 mutated and
28 wild-type samples at diagnosis. All 11 WT1-mutated diagnostic
samples showed the same mutation at relapse. In 2 cases, an
additional WT1 mutation was gained, which was situated on the
other WT1 allele as determined by cloning. No loss of WT1
mutations was observed. Four of the 28 (14%) samples gained a
WT1 mutation at relapse. Two of these patients in fact gained
2 mutations: in one patient, this concerned mutations in exon 7 and
exon 10; in the other patient, in exon 4 and exon 7.
Relationship between WT1 mutations and clinical and genetic
characteristics
The frequency of WT1 mutations was significantly related to age;
below the age of 3 years, only 1 of 60 (2%) cases was WT1-
mutated; in the age group greater than or equal to 3 years and less
than 10 years, we found the highest frequency (17/76  18%); and
in children at the age of 10 years or above, the frequency decreased
(17/145  12%; P  .008). The white blood cell count (WBC) at
diagnosis was significantly higher in WT1-mutated AML patients
(median 57.2  109/L) than in WT1 wild-type AML patients
(median 34.1  109/L; P  .007). No significant differences be-
tween the 2 groups were found for sex (P  .81) or for French-
American-British (FAB)–type distribution (P  .60).
WT1 mutations were not randomly distributed over the different
cytogenetic subgroups (Figure 3). Twenty-one of 94 (22.3%)
CN-AML cases harbored WT1 mutations compared with 13 of
187 (7.0%) cases with cytogenetic aberrations (P  .001). No
mutations were found in the favorable karyotype subgroups t(8;21)
and inv(16), and in the t(15;17) and in the MLL-rearranged AML
cases, only an occasional WT1 mutation was found. However,
Figure 3. Clustering of the WT1 gene mutations in the subgroup of childhood
CN-AML. WT1 mutations mainly clustered in the CN-AML subgroup. No mutations
were found in the CBF-AML subgroup [ie, t(8;21) and inv(16)], and very few were
detected in the t(15;17) and in the MLL gene–rearranged childhood AML cases.
Mutations were also found in the subgroup with other karyotypes, but at a lower
frequency (14.8%) than in the CN-AML subgroup (22.3%).
Figure 2. Location of the WT1 gene mutations and
their overlap with MRD detection areas. The location of
the WT1 gene mutations detected in initial diagnosis and
relapse childhood AML samples is schematically pre-
sented according to the exon structure of the WT1 gene.
Two areas of mutational hotspots were identified in exon
7. Two pairs of primer-probe combinations currently used
for WT1-based MRD detection are also depicted in the
figure and show overlap with the locations of the
mutations.
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within the subgroup with “other cytogenetic aberrations” (defined
as all other cytogenetic aberrations than the mentioned subgroups),
9 of 61 (14.8%) samples were WT1-mutated. Two of these
9 patients carried a t(6;9)(p23;q34) and another 2 patients carried a
9q-deletion. The other patients in this subgroup did not have
cytogenetic aberrations in common.
WT1-mutated patients were more likely to harbor a FLT3/ITD
(43% vs 17% of the WT1 wild-type samples; P  .001) and a
CEBP mutation (19% vs 7%, respectively; P  .03; Table 2).
WT1 and NPM1 mutations were mutually exclusive. WT1 muta-
tions and c-KIT mutations and MLL-PTD were also mutually
exclusive, however, this was based on small numbers only. Within
the CN-AML subgroup, we also identified FLT3/ITD to be
significantly associated with WT1 mutations (58% vs 30% for WT1
mutated and WT1 wild-type patients, respectively; P  .03). How-
ever, no difference in CEBP mutations (17% of the WT1-mutated
vs 15% of the WT1 wild-type samples; P  1.00) was found in the
CN-AML subgroup. WT1 mutations and NPM1 mutations were
also mutually exclusive in the CN-AML subgroup (P  .01).
The study population included 8 patients with a secondary
AML. Two of these patients (1 patient with AML after a preceding
MDS and 1 therapy-related AML) harbored a WT1 mutation.
Prognostic impact of WT1 mutations in childhood AML
The median follow-up time for survivors was 4.4 years (4.4 years
for WT1 mutated vs 4.4 years for WT1 wild-type AML patients;
P  .89).
The CR rate did not differ significantly between patients with
WT1-mutated and WT1 wild-type AML (74.1% vs 86.3%, respec-
tively; P  .09). However, RD was significantly more frequent in
the former group (23.1% vs 8.8%, respectively; P  .03). Patients
with WT1-mutated AML had a significantly worse pOS, pEFS, and
CIR than WT1 wild-type AML patients (5 years pOS 35 
 10% vs
66% 
 4%; P  .002; pEFS 22 
 8% vs 46% 
 4%; P  .001;
and CIR 70% 
 10% vs 44% 
 4%; PGray  .001, respectively;
Figure 4). The median time to relapse from CR1 was significantly
shorter for the WT1-mutated cases (8.5 months) than for the WT1
wild-type cases (11.4 months; P  .02).
Figure 4. Survival curves of childhood AML patients with and without WT1
mutations. Kaplan-Meier estimates for 5-year pOS (A) and pEFS (B), showing
log-rank P values. The 5-year CIR is depicted in (C) and was analyzed according to
the Kalbfleisch and Prentice method using the Gray test for statistical significance.
WT1-mutated AML patients have a significantly worse outcome in terms of OS, EFS,
and CIR compared with patients with WT1 wild-type AML.
Table 3. Five-year OS according to combined WT1 and FLT3/ITD
mutational status
FLT3/ITD
status
WT1 mutational status
PWild-type Mutant
Negative 67% 
 4% (n  176) 49% 
 14% (n  14) .20
Positive 63% 
 9% (n  29) 21% 
 12% (n  13)  .01
P .61 .09
Percentages are 
SE.
Table 4. Five-year EFS according to combined WT1 and FLT3/ITD
mutational status
FLT3/ITD
status
WT1 mutational status
PWild-type Mutant
Negative 48% 
 4% (n  176) 29% 
 12% (n  14) .07
Positive 34% 
 10% (n  29) 15% 
 10% (n  13)  .01
P .32 .16
Percentages are 
SE.
Table 5. Five-year CIR according to combined WT1 and FLT3/ITD
mutational status
FLT3/ITD
status
WT1 mutational status
PWild-type Mutant
Negative 42% 
 4% (n  176) 64% 
 15% (n  14) .04
Positive 55% 
 13% (n  29) 77% 
 14% (n  13) .02
P .27 .18
Percentages are 
SE.
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Although numbers were small, there were no differences in CR rate,
pOS, pEFS, and CIR between WT1-mutated patients with one (n 13)
or more than one (n 14) affected allele (data not shown).
As WT1 mutations were frequently associated with FLT3/ITD,
we analyzed the impact on outcome according to the combined
mutational status (Tables 3-5). Although numbers are small, we
found that, both in the FLT3/ITD negative and in the FLT3/ITD
positive subgroup, WT1 mutated cases had a worse pEFS and CIR
than the WT1 wild-type cases. However, this only translated in a
significant survival disadvantage for the WT1 mutated AML
patients in the FLT3/ITD positive subgroup; in the FLT3/ITD
positive subgroup, the 5-year pOS was 21% (
12%) for patients
with WT1-mutated AML and 63% (
9%; P  .01) for WT1
wild-type cases. In the FLT3/ITD negative subgroup, these figures
were 49% (
 14%) versus 67% (
4%; P  .20). Conversely, we
found no significant impact on outcome of FLT3/ITD in the
subgroups of WT1 mutated or wild-type AML patients.
Prognostic analysis restricted to the CN-AML subgroup
In the CN-AML subgroup, the CR rate was worse in the 19 patients
with WT1-mutated AML (74%) than in the 66 WT1 wild-type AML
patients (91%; P  .05). There also was a trend for RD to occur
more frequently in patients with WT1 mutated AML (22% vs 6%;
P  .07). WT1 mutated CN-AML patients had lower pOS and
pEFS and higher CIR than WT1 wild-type CN-AML patients
(5-year pOS 44% 
 12% vs 69% 
 6%, P  .03; pEFS
32% 
 11% vs 49 
 6%, P  .02; and CIR 41% 
 7% vs
58% 
 13%, PGray  .06, respectively).
Multivariate analysis
WT1 mutations were included in a Cox regression model, including age
(using 10 years of age as cutoff value), WBC at diagnosis (using
50 109/L), cytogenetic subgroups [favorable karyotype, ie, inv(16)
and t(8;21), normal karyotype, and other karyotype], FLT3/ITD, and
SCT as time-dependent covariable. We identified WT1 mutations as an
independent adverse risk factor for pOS [hazard ratio (HR) 1.79; 95%
confidence interval (CI) 1.02-3.14; P .041], pEFS (HR 2.05; 95% CI
1.24-3.38; P .005), as well as for CIR (HR 2.44; 95% CI 1.42-4.17;
P .001; Table 6). Inclusion of NPM1 and CEBP mutations in the
model did not change the HRs for WT1 mutations. When we entered
FLT3/ITD with high allelic ratios (cutoff value 0.4 or the me-
dian 0.66) or FLT3/ITD with large ITD length (median 55 bp) in
the model, this did not change the results.
Discussion
Our study shows that WT1 mutations occur in approximately 12% of
samples from diagnostic childhood AML patients, which is comparable
to the frequency found in a smaller study on childhood AML reporting
WT1 mutations in 4 of 41 patient samples (10%).8 Recently, several
large adult AML series were reported, showing frequencies of WT1
mutations ranging from 10% to 13%.12-14,28 However, these series were
restricted to CN-AML. We found a higher percentage in this particular
AML subgroup (ie, 22%). It therefore seems that there is a higher
frequency of WT1 gene mutations in childhood AML compared with
adult AML. Further support for this difference comes from the typical
age pattern that was observed, with a peak frequency in children
between the ages of 3 and 10 years. Mutations were sporadically found
in children younger than 3 years old, and after the age of 10 years, there
was a decreasing frequency. Of interest, 2 other molecular aberrations
that also occur frequently within the CN-AML subgroup (ie, NPM1
mutations and FLT3/ITD) both show a different age pattern, as their
frequency increases with increasing age.4,6 Although not all patients
were screened for WT1 mutations in exons 1 to 6, we do not expect this
to significantly increase the mutation frequency, as these mutations were
only sporadically found in absence of a WT1 exon 7 mutation.
Our study identifies the presence of WT1 mutations as a novel poor
prognostic risk factor for childhood AML. The 5-year overall survival
for WT1-mutated AML patients was only 37% compared with 67% for
the WT1 wild-type AML patients. This was due to a significant increase
in the number of events in the WT1-mutated subgroup, including both
primary resistant disease, which was found in 23% of WT1-mutated
AML patients, as well as an increased frequency of relapse. This was
observed both in the overall group as well as in the CN-AML subset;
although some of the differences did not reach statistical significance in
the CN-AML subgroup. Multivariate analysis showed that WT1 muta-
tions had strong prognostic significance, independent from other well-
known risk factors in childhood AML, with a 2.4-fold increased risk to
relapse despite current intensive chemotherapy. When we combined
2 risk factors (ie, WT1 mutations and FLT3/ITD), a very poor risk group
was detected with a 5-year overall survival of only 21%. This indicates
an additive effect of carrying both mutations with respect to outcome.
Our data need to be prospectively validated, given the retrospective
nature of this cell-bank study. However, comparable results regarding
outcome have been reported in most, but not all, studies in adults with
CN-AML.13,14,28
In almost half of the patients WT1 mutations are associated with a
FLT3/ITD, which is a well-known poor prognostic factor in childhood
AML, especially in case of a high mutant/wild-type allelic ratio (AR).29
Moreover, a recent study also showed that the ITD length has prognostic
impact in childhood AML.30 We did not find differences in the ARs and
ITD lengths of the associated FLT3/ITDs between WT1-mutated and
wild-type AML patients. WT1 and NPM1 mutations were mutually
exclusive and, respectively, predict for poor and excellent outcome in
the CN-AML subgroup.4 However, when including NPM1 mutations in
the multivariate analysis, WT1 mutations still had independent prognos-
tic significance. In the overall cohort, WT1 mutations were also
associated with CEBP mutations; this association disappeared in the
CN-AML subgroup. As CEBPmutations are also known to cluster in
Table 6. Results of multivariate analysis for OS, EFS, and RFS
Outcome/variable HR (95% CI) P
OS
Other karyotype 2.83 (1.68-4.77)  .001
FLT3/ITD 1.89 (1.07-3.34) .03
Favorable karyotype 0.39 (0.15-0.96) .04
WT1 1.79 (1.02-3.14) .04
EFS
Other karyotype* 2.33 (1.49-3.64)  .001
WT1 2.05 (1.24-3.38) .005
FLT3/ITD 1.82 (1.14-2.92) .01
Favorable karyotype 0.74 (0.41-1.33) .31
FS
Other karyotype* 2.44 (1.48-4.02)  .001
WT1 2.44 (1.42-4.17) .001
FLT3/ITD 1.99 (1.19-3.34) .009
Favorable karyotype 0.84 (0.44-1.58) .58
WT1 mutations were tested in a Cox regression model with other well-known risk
factors in childhood AML including favorable cytogenetics t(8;21), inv16, other
abnormal karyotypes, and FLT3/ITD. When including age  10 years, WBC 
50  109/L, and SCT as time-dependent covariable, the estimates for WT1 mutations
were similar, and the P values for these 3 parameters were all  .10.
*Other karyotypes indicates all other cytogenetic aberrations than the well-known
childhood AML subgroups, that is, normal karyotype and the favorable karyotypes
inv(16) and t(8;21).
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CN-AML, the observed association in the overall group may be biased.
The identification of WT1 mutations adds to the recognition of CN-
AML as a heterogeneous subgroup with various molecular abnormali-
ties in childhoodAML, which may be important for future classification
and risk-group stratification in childhood CN-AML.
Mutations in the WT1 gene are localized in 2 hotspot areas in exon 7.
However, we also detected mutations in other exons. The mutational
hotspots are in agreement with the location of mutations found in
previous AML studies, but mutations in exons 4 and 10 have not been
reported before.8,9,13,14,28 Of interest, the affected mutated areas overlap
with different primer-probe combinations used for WT1-based MRD
detection, as reported in the literature.21,31,32 One of these combinations
was used in our study for the expression analysis of the WT1 mutants.21
All WT1-mutated samples showed presence of mRNA expression.
Surprisingly, expression was also picked up in 3 samples with mutations
exactly located at the binding site of the reversed primer, indicating no
large effect of these mutations on the PCR amplification, and therewith
WT1-based MRD detection. However, a previous case report did show a
negative effect on the expression level of WT1 in a sample in which a
mutation was gained at the primer binding site. Another potential
problem for using WT1 as an MRD marker may be the gain of mutations
at relapse, which was observed in 14% of our relapse samples. Future
studies on serial samples taken in the course of the disease need to assess
the impact of mutations on MRD detection based on WT1 expression
levels.
At least 43% of the patients with WT1-mutated AML had more than
one affected WT1 allele in their leukemic cells. This frequency may be
higher, as not all WT1-mutated samples could be screened for additional
mutations in exons 1 to 6. Furthermore, to search for additional second
hits in the WT1-mutated AML patients, we also screened for small WT1
deletions using MPLA, but only one extra patient was revealed with a
deletion besides a mutation. So far, we were able to detect a second
affected allele in approximately half of the WT1-mutated AML patients.
Sequence analysis of the cDNA of mutated samples showed expression
of the mutated as well as the wild-type transcript in samples with one
affected allele. This either suggests a dominant or dominant-negative
mechanism of the mutated WT1 protein in the subset of patients with
only one affected allele, or other mechanisms of silencing of the
wild-type allele such as silencing on RNA level. Epigenetic silencing is
unlikely as the wild-type allele is expressed. Of interest, there was no
apparent difference in outcome between patients with one affected allele
versus those with more than one affected allele. Until now, the precise
function of WT1 in hematopoiesis is still unclear, as well as whether
WT1 acts as an oncogene or tumor suppressor gene inAML, which issue
was recently reviewed by Yang et al33 Further research is needed to
elucidate the underlying functional mechanisms of the mutated WT1
protein and the pathways involved leading to therapy resistance in these
patients.
In conclusion, our study showed the presence of WT1 mutations
in 12% of diagnostic childhood AML samples and clustering of
these mutations in the CN-AML subgroup (22%). WT1 mutations
are a novel independent poor prognostic factor in childhood AML.
In particular, patients with AML carrying both a WT1 mutation and
a FLT3/ITD have a very poor outcome of only 21% 5-year survival
in this series. Further exploration of the biology of WT1-mutated
AML is necessary to better understand the mechanisms of therapy
resistance. This may reveal new potential therapeutic targets for
these patients who suffer from a very poor outcome despite current
intensive chemotherapy.
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